Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adventrx Pharmaceuticals, Inc.
ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
February 20th, 2009
ADVENTRX Pharmaceuticals, Inc. (NYSE Alternext US: ANX), announced that it has completed patient enrollment in its bioequivalence study of ANX-514 (docetaxel emulsion for injection). The Company is on track to announce results from this study in the second quarter of 2009. ANX-514 is a reformulation of the blockbuster chemotherapeutic agent, Taxotere(R), an anti-cancer agent that is approved to treat breast, non-small cell lung, prostate, head and neck & gastric cancers. In 2007, the aggregate worldwide market for Taxotere was in excess of $3 billion. The study is a multi-center, open-label, randomized two-period crossover comparison of ANX-514 and...
Source: Health Business Week (2009-02-20)
|
